目的 探討血必凈注射液聯(lián)合注射用哌拉西林鈉他唑巴坦鈉治療膿毒癥的效果。方法 選取2022年2月—2024年1月蘇州第九人民醫(yī)院收治的96例膿毒癥患者資料，根據(jù)用藥差別將患者分為對(duì)照組（50例）和治療組（46例）。對(duì)照組靜滴注射用哌拉西林鈉他唑巴坦鈉，4.5 g藥物以20 mL滅菌注射用水充分溶解后與100 mL生理鹽水混勻，1次/8 h。治療組在對(duì)照組基礎(chǔ)上靜滴血必凈注射液，將100 mL藥品與100 mL生理鹽水混勻，2次/d。兩組患者治療7 d后評(píng)估療效。比較兩組臨床療效、病情程度、血清炎性因子。結(jié)果 治療組的總有效率為86.96%，對(duì)照組的總有效率為70.00%，組間比較差異顯著（P＜0.05）。治療后，兩組急性生理與慢性健康評(píng)分（APACHE Ⅱ）、序貫器官衰竭評(píng)分（SOFA）評(píng)分均降低（P＜0.05），且治療組的APACHE Ⅱ、SOFA評(píng)分均低于對(duì)照組（P＜0.05）。治療后，兩組血清降鈣素原（PCT）、高遷移率蛋白1（HMGB1）、白細(xì)胞介素-6（IL-6）、C反應(yīng)蛋白（CRP）水平均降低（P＜0.05），且治療組血清PCT、HMGB1、IL-6、CRP水平低于對(duì)照組（P＜0.05）。結(jié)論 在注射用哌拉西林鈉他唑巴坦鈉治療基礎(chǔ)上加用血必凈注射液可提高膿毒癥的臨床療效，促進(jìn)疾病轉(zhuǎn)歸，減輕炎癥反應(yīng)。

Objective To explore the efficacy of Xuebijing Injection combined with Piperacillin Sodium and Tazobactam Sodium for injection in treatment of sepsis. Methods Clinical data from 96 sepsis patients admitted to Suzhou Ninth People’s Hospital from February 2022 to January 2024 were selected, and the patients were divided into control group (50 cases) and treatment group (46 cases) based on medication differences. The control group received intravenous infusion of Piperacillin Sodium and Tazobactam Sodium for injection, 4.5 g drug fully dissolved in 20 mL sterile injection water and mixed with 100 mL physiological saline for once per 8 h. The treatment group received intravenous infusion of Xuebijing Injection on the basis of the control group, and 100 mL drug was mixed with 100 mL physiological saline, twice daily. The efficacy of two groups of patients was evaluated after 7 d of treatment. The clinical efficacy, severity of illness, and serum inflammatory factors were compared between two groups. Results The total effective rate of the treatment group was 86.96%, while the total effective rate of the control group was 70.00%, and the difference was significant between two groups (P < 0.05). After treatment, APACHE II and SOFA scores of two groups decreased (P < 0.05), and APACHE II and SOFA scores of the treatment group were lower than those of the control group (P < 0.05). After treatment, the serum levels of PCT, HMGB1, IL-6, and CRP in two groups decreased (P < 0.05), and the serum levels of PCT, HMGB1, IL-6, and CRP in the treatment group were lower than those in the control group (P < 0.05). Conclusion The combination of Xuebijing Injection and Piperacillin Sodium and Tazobactam Sodium for injection can improve clinical efficacy in treatment of sepsis, promote disease progression, and alleviate inflammatory reactions.

R977

蘇州市第九人民醫(yī)院科研啟動(dòng)基金立項(xiàng)項(xiàng)目（YK202121）